Cyclo Therapeutics Stock Z Score
CYTHDelisted Stock | USD 0.72 0.06 9.09% |
Cyclo |
Cyclo Therapeutics Company Z Score Analysis
Cyclo Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
CompetitionIn accordance with the company's disclosures, Cyclo Therapeutics has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and about the same as Health Care (which currently averages 0.0) industry. The z score for all United States stocks is 100.0% higher than that of the company.
Cyclo Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclo Therapeutics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclo Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclo Therapeutics by comparing valuation metrics of similar companies.Cyclo Therapeutics is currently under evaluation in z score category among its peers.
Cyclo Fundamentals
Return On Equity | -226.64 | |||
Return On Asset | -2.84 | |||
Operating Margin | (35.46) % | |||
Current Valuation | 34.87 M | |||
Shares Outstanding | 32.74 M | |||
Shares Owned By Insiders | 48.45 % | |||
Shares Owned By Institutions | 11.44 % | |||
Number Of Shares Shorted | 736.31 K | |||
Price To Book | 59.10 X | |||
Price To Sales | 27.09 X | |||
Revenue | 1.08 M | |||
Gross Profit | 794.48 K | |||
EBITDA | (20.03 M) | |||
Net Income | (20.06 M) | |||
Cash And Equivalents | 4.29 M | |||
Cash Per Share | 0.51 X | |||
Total Debt | 1.03 M | |||
Current Ratio | 2.93 X | |||
Book Value Per Share | (0.47) X | |||
Cash Flow From Operations | (16.19 M) | |||
Short Ratio | 5.58 X | |||
Earnings Per Share | (0.90) X | |||
Target Price | 0.95 | |||
Beta | -0.57 | |||
Market Capitalization | 23.59 M | |||
Total Asset | 13.25 M | |||
Retained Earnings | (83.86 M) | |||
Working Capital | 3.85 M | |||
Net Asset | 13.25 M |
About Cyclo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
USOI | Credit Suisse X Links | |
ULTY | Tidal Trust II | |
CONY | YieldMax N Option | |
BCAT | BlackRock Capital Allocation | |
PDI | Pimco Dynamic Income |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Cyclo Stock
If you are still planning to invest in Cyclo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyclo Therapeutics' history and understand the potential risks before investing.
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |